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Summary Purpose. This phase II, open-label, multicenter
study assessed the oral, multitargeted, tyrosine kinase
inhibitor sunitinib in patients with advanced gastric or
gastroesophageal junction adenocarcinoma who had re-
ceived prior chemotherapy. Experimental design. Patients
received sunitinib 50 mg/day on Schedule 4/2 (4 weeks on
treatment, followed by 2 weeks off treatment). The primary
endpoint was objective response rate; secondary endpoints
included clinical benefit rate, duration of response,
progression-free survival (PFS), overall survival (OS),
pharmacokinetics, pharmacodynamics, safety and tolerabil-
ity, and quality of life. Results. Of 78 patients enrolled,
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DOI 10.1007/s10637-010-9438-ymost had gastric adenocarcinoma (93.6%) and metastatic
disease (93.6%). All were evaluable for safety and efficacy.
Two patients (2.6%) had partial responses and 25 patients
(32.1%) had a best response of stable disease for ≥6 weeks.
Median PFS was 2.3 months (95% confidence interval [CI],
1.6–2.6 months) and median OS was 6.8 months (95% CI,
4.4–9.6 months). Grade ≥3 thrombocytopenia and neutro-
penia were reported in 34.6% and 29.4% of patients,
respectively, and the most common non-hematologic
adverse events were fatigue, anorexia, nausea, diarrhea,
and stomatitis. Pharmacokinetics of sunitinib and its active
metabolite were consistent with previous reports. There
were no marked associations between baseline soluble
protein levels, or changes from baseline, and measures of
clinical outcome. Conclusions. The progression-delaying
effect and manageable toxicity observed with sunitinib in
this study suggest that although single-agent sunitinib has
insufficient clinical value as second-line treatment for
advanced gastric cancer, its role in combination with
chemotherapy merits further study.
Keywords Sunitinib.Gastric cancer.Tyrosine kinase
inhibitor.Pharmacokinetics.Pharmacodynamics
Introduction
Gastric cancer is the fourth most common cancer globally,
with an estimated 934,000 new cases in 2002 [1]. Patients
presenting or relapsing with metastatic disease have a poor
prognosis, and with 700,000 deaths annually, gastric cancer
is the second most common cause of death from cancer
worldwide [1]. In Japan and Korea, mass screening has led
to a shift towards diagnosis at earlier stages of the disease,
and the 5-year survival rate is relatively high at 40–60% [2,
3]. Globally, 5-year survival is lower, at approximately 20%
[2]. In clinical trial patients with advanced gastric cancer,
reported median survival commonly ranges from
8 months to 11 months in the first-line treatment setting
and approximately 5 months to 6 months in the second-
line treatment setting [4–6].
Combination chemotherapy prolongs survival and
improves quality of life in patients with gastric cancer,
compared with best supportive care [7, 8]. Recently, a
meta-analysis showed a small but significant survival
benefit for combination chemotherapy versus single-agent
chemotherapy, though at a cost of higher toxicity [8]. There is
no globally accepted standard regimen for first-line treatment
of advanced gastric cancer, though a 5-fluorouracil-based
regimen in combination with a platinum analog is reported
to be the most widely accepted regimen [9]. As yet, there are
no data showing acceptable efficacy for gastric cancer in the
second line setting. New treatment strategies are still needed
to improve the survival of patients with advanced gastric
cancer, both in the first-line treatment setting and in those
patients whose disease has progressed during or after
chemotherapy.
Tumor angiogenesis, growth, and metastasis can be
inhibited by blocking receptor tyrosine kinases (RTKs),
including vascular endothelial growth factor receptors
(VEGFRs) and platelet-derived growth factor receptors
(PDGFRs), which are both expressed or overexpressed in
gastric cancer [10–12]. VEGF and PDGF-A expression have
been linked to tumor progression and poor survival in gastric
cancer [13, 14], and both VEGF and VEGFR expression
have been correlated with increasing stage of disease [15].
Treatments that specifically interrupt RTK signalling path-
ways have been investigated in phase II studies in advanced
gastric cancer, including a study of single-agent gefitinib
[16, 17] and targeted therapies such as bevacizumab [18],
cetuximab [19, 20], and erlotinib [21] in combination with
chemotherapy. These targeted agents act through a single
receptor pathway. However, many gastric tumors co-express
several RTKs [10] and drugs targeting multiple RTKs
involved in angiogenesis may deliver additional benefits
relative to single receptor target inhibition.
Sunitinib malate (SUTENT®; Pfizer Inc., New York, NY) is
anoral,multitargetedtyrosinekinaseinhibitorofVEGFR-1,-2,
and -3, PDGFR-α and -β, and several other related RTKs
[22–24]. In a murine xenograft model of gastric carcinoma,
sunitinib exhibited antiangiogenic and antitumor activity at a
dose of 40 mg/kg/day (Pfizer Inc. Data on file). At a dose of
50 mg/day given on Schedule 4/2 (4 weeks on treatment
followed by 2 weeks off treatment), sunitinib has demonstrat-
ed superior efficacy to previous standard treatments and
acceptable tolerability in gastrointestinal stromal tumors
refractory or intolerant to imatinib, and advanced renal cell
carcinoma [25, 26]. This phase II trial investigated the use of
single-agent sunitinib in patients with previously-treated,
advanced gastric carcinoma.
Materials and methods
Patients
Patients eligible for inclusion were males and females aged
≥18 years with histologically or cytologically confirmed
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junction adenocarcinoma (i.e. adenocarcinoma with >50%
extension in the stomach) that was not amenable to surgery,
radiation, or combined modality therapy with curative
intent, and who had disease progression or recurrence after
treatment with one prior chemotherapy regimen for ad-
vanced or metastatic disease (last dose ≥4 weeks before
study entry).
Patients who had received prior adjuvant therapy were
eligible if relapse occurred >6 months after completing
adjuvant treatment and had received one regimen for
relapsed disease. Those who had received prior palliative
radiotherapy to metastatic lesions were also eligible, if at
least one measurable lesion had not been irradiated. Patients
were excluded if they had: major surgery or radiation
therapy <4 weeks before starting study treatment; grade 3
hemorrhage (based on the National Cancer Institute [NCI]
Common Terminology Criteria for Adverse Events
[CTCAE]) <4 weeks before starting study treatment;
presence of clinically relevant ascites (requiring paracent-
esis) and/or grade ≥2 weight loss; active inflammatory
bowel disease, partial or complete bowel obstruction, or
chronic diarrhea; known brain metastases, spinal cord
compression, or carcinomatous meningitis; uncontrolled
hypertension; clinically significant cardiovascular disease
(severe/unstable angina, myocardial infarction, coronary
artery bypass graft, symptomatic congestive heart failure),
pulmonary embolism, or cerebrovascular accident within
12 months prior to study drug administration; ongoing
cardiac dysrhythmias (NCI CTCAE grade ≥2), atrial
fibrillation, or prolongation of the QTc interval; or any
other severe acute or chronic medical or psychiatric
condition making the patient inappropriate for entry into
the study in the judgment of the investigator.
All patients had: measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST);
Eastern Co-operative Oncology Group (ECOG) perfor-
mance status of 0 or 1; adequate hepatic, renal, and
hematologic function; and life expectancy of ≥3 months;
and were required to provide written, informed consent.
Study design and treatment
In this phase II, open-label, 2-stage, multicenter study,
patients received oral sunitinib 50 mg/day on Schedule 4/2
(4 weeks on treatment, followed by 2 weeks off treatment)
in repeated 6-week cycles, until disease progression,
unacceptable toxicity, or withdrawal of consent. Dose
reduction to 37.5 mg/day and then to 25 mg/day was
allowed, and therapy could be interrupted or delayed for up
to 4 weeks according to individual tolerability.
The primary objective of this study was to determine the
antitumor activity of single-agent sunitinib in this popula-
tion. The primary endpoint was the overall objective
response rate (ORR), defined as the percentage of all
patients who experienced a confirmed complete response
(CR) or partial response (PR), as defined by RECIST [27].
Secondary endpoints included duration of response (in
those with an objective response of CR or PR); clinical
benefit rate (CBR, defined as the percentage of patients
with CR, PR, or stable disease [SD] ≥24 weeks);
progression-free survival (PFS); time to progression
(TTP); OS; one-year survival rate; safety and tolerability;
health-related quality of life (HRQoL); and measurement of
trough sunitinib and SU12662 (the major active metabolite
of sunitinib) plasma levels, as well as levels of plasma
biomarkers (VEGF, soluble (s) VEGFR2, sVEGFR3, and
sKIT). This study was approved by the institutional review
board of each participating center and was performed in
accordance with the International Conference on Harmoni-
zation Good Clinical Practice guidelines, as well as
applicable local laws and regulatory requirements.
Assessments
Tumor response was assessed according to RECIST version
1.0, with a minor modification such that lesions assessed
using spiral computed tomography (CT) scan qualified as
measurable if they were twice the reconstruction interval
used (up to 8 mm) and at least 10 mm at baseline. Tumor
response was assessed: on day 28 of every cycle; whenever
disease progression was suspected; to confirm a CR or PR
(at least 4 weeks after initial documentation of response);
and at the end of study treatment or withdrawal from the
study. Tumors were imaged using CT scan or magnetic
resonance imaging.
Safety was assessed at regular intervals by monitoring
and recording adverse events and by measuring hematology
and clinical chemistries. Additional safety assessments
included 12-lead electrocardiograms, vital signs, physical
examination, and ECOG performance status. Adverse
events were graded using NCI CTCAE, version 3.0.
Blood samples were taken for pharmacokinetic analysis
of sunitinib and SU12662 prior to sunitinib treatment on
study day 1, on days 14 and 28 of the first treatment cycle,
on days 1 and 28 of cycles 2 and 3, and on day 28 of
cycle 5. Sunitinib and SU12662 concentrations were
analyzed using a validated, sensitive, and specific isocratic
liquid chromatographic tandem mass spectrometric method,
as previously described [28]. Blood samples for biomarker
assessment were taken prior to sunitinib treatment on study
day 1, on days 14 and 28 of the first treatment cycle, on
days 1 and 28 of cycle 2, and on day 28 of cycle 5.
Patient-reported outcomes were assessed using the
validated, self-administered European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
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specific questionnaire QLQ-STO22 [29, 30]. The question-
naires were completed on the first day of each cycle during
a patient’s clinic visit prior to other clinical activities
including the administration of the study drugs, and at the
end of treatment or withdrawal from the study.
Statistical considerations
This study followed a 2-stage Simon design. If ≤1o b j e c t i v e
response (CR or PR) was observed in the first 38 eligible
patients, then enrollment to the study would end. If ≥2o f
these patients achieved a CR or PR, then the study was
planned to proceed to Stage 2 by enrolling 25 additional
patients. Based on Simon’s 2-stage design, this study had
85% power to reject the null hypothesis of a 5% response
rate (considered not clinically meaningful) when the true
response rate for sunitinib was ≥15% (considered favorable
in this patient population). With a significance level (α)o f
5%, 63 eligible patients were required, and at the end of the
study, the null hypothesis would be rejected if ≥7o b j e c t i v e
tumor responses were observed.
The study population for all analyses was defined as
the number of patients enrolled in the study who
received at least one dose of sunitinib, and (for analysis
of ORR, duration of response, CBR, TTP, and PFS) had
measurable disease at baseline. The number (%) of
patients who achieved an objective response was sum-
marized along with the corresponding 95% exact confi-
dence interval (CI). Time-to-event variables, 1-year
survival rate, and a 2-sided 95% CI were estimated and
summarized using the Kaplan-Meier method.
Results
Patient characteristics and study treatment
In total, 78 patients were enrolled in the study (Fig. 1), of
whom 73 (93.6%) had a diagnosis of gastric adenocarcino-
ma, and 5 (6.4%) had adenocarcinoma of the gastroesoph-
ageal junction. A total of 73 patients (93.6%) had metastatic
disease. Baseline characteristics are summarized in Table 1.
The median duration of treatment was 1.6 months
(range, 0.1–15.4), and the median number of cycles started
was 2 (range, 1–17). Fourteen patients (17.9%) required at
least one dose reduction to 37.5 mg/day, mainly due to
hematologic adverse events; three of these patients had ≥2
dose reductions. Median relative dose intensity was 93.5%.
The relative dose intensity was highest during cycles 1 and
2 (96.4% and 100%, respectively) and ranged from 50.0%
to 96.4% during cycles 3–17. Sixteen patients (20.5%)
required one or more doses of sunitinib to be delayed, with
12 dose delays lasting for ≥1 week, 6 for ≥2 weeks, and 1
for ≥3 weeks. Reasons for study discontinuation were lack
of efficacy (n=55), adverse events (n=11), death (n=8),
and withdrawal of consent (n=2).
During follow-up, among 69 patients for whom data
were available, 39 received post-study chemotherapy; the
most common regimens were single-agent taxanes, FOL-
FIRI or FOLFOX, or cisplatin-based combinations. Japa-
nese and Korean patients were most likely to receive later
lines of chemotherapy (approximately 75% of enrolled
patients) but no significant differences were noted in the
types of chemotherapy delivered. Five patients received
radiotherapy during the follow-up period, and one under-
went surgical resection of metastatic ovarian cancer.
Efficacy
All 78 patients had measurable disease at baseline and were
included in the efficacy analyses. Two patients achieved
confirmed investigator-determined PR, with a response
duration of 20 weeks in one patient and at least 6 weeks
(before study discontinuation) in the other patient. Both
patients achieving a PR were enrolled in Stage 1 of the
study, hence the study proceeded to Stage 2. However, with
no further responses seen during Stage 2, the primary
endpoint of the study was not met, with an ORR of 2.6%.
Twenty-five patients (32.1%) had stable disease (SD) for
≥6 weeks, including four patients (5.1%) experiencing SD
lasting ≥24 weeks. The clinical benefit rate was 7.7%.
Fig. 1 Patient disposition. ITT, intention-to-treat. RECIST, Response
Evaluation Criteria in Solid Tumors
1452 Invest New Drugs (2011) 29:1449–1458Forty-two patients (53.8%) experienced disease progres-
sion; the remaining nine patients (11.5%) had missing
evaluations or were not evaluable.
By intent-to-treat analysis (n=78), median TTP was
2.3 months (95% CI, 1.7–2.6 months), median PFS was
2.3 months (95% CI, 1.6–2.6 months; Fig. 2a), and median
OS was 6.8 months (95% CI, 4.4–9.7 months; Fig. 2b). The
probability of 1-year survival was 24.2% (95% CI,
14.4–34.1%).
Pharmacokinetics and pharmacodynamics
Steady-state observed trough concentrations (Ctrough) were
dose-corrected to the starting dose (i.e. reference dose)
where appropriate, to adjust for individual dose changes
during the study. Mean, dose-corrected, plasma Ctrough on
day 28 (steady state) of cycles 1, 2, 3, and 5 ranged from
62.2 ng/mL to 65.6 ng/mL for sunitinib, 26.0 ng/mL to
33.7ng/mLforitsactivemetaboliteSU12662,and90.7ng/mL
to 97.9 ng/mL for total drug (sunitinib + SU12662),
respectively. The mean dose-corrected Ctrough box plot of
the total drug concentration versus cycle/day is displayed in
Fig. 3. No unexpected accumulation of sunitinib and
SU12662 was observed throughout the study.
Baseline soluble protein (biomarker) levels or changes
from baseline at each time point were analyzed in patients
stratified by tumor response category (clinical benefit [PR
Patients receiving sunitinib (N=78)
Median age (range), years 56 (25–78)
Gender (male/female), n (%) 56 (71.8) / 22 (28.2)
ECOG PS, n (%)
0 26 (33.3)
1 52 (66.7)
Histopathology, n (%)
Gastric adenocarcinoma 73 (93.6)
Gastroesophageal junction
adenocarcinoma
5 (6.4)
Histological grade, n (%)
Well differentiated 9 (11.5)
Moderately differentiated 26 (33.3)
Poorly differentiated 35 (44.9)
Undifferentiated 3 (3.8)
Cannot be assessed 5 (6.4)
Extent of disease, n (%)
Locally advanced 5 (6.4)
Metastatic 73 (93.6)
Prior treatment, n (%)
Chemotherapy 78 (100.0)
Radiation therapy 6 (7.7)
Surgery 59 (75.6)
Table 1 Patient baseline
characteristics
ECOG PS Eastern Co-operative
Oncology Group performance
status
Fig. 2 Kaplan-Meier curve of a progression-free survival and b
overall survival following treatment with sunitinib 50 mg/day on
Schedule 4/2
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associations with clinical benefit were only observed
between high sKIT ratio to baseline at cycle 1 day 28
(P=0.0081), and between low VEGF-C ratio at cycle 2
d a y1( P=0.0326), though the number of patients with
clinical benefit was relatively small (n=6). Analysis of
patients stratified according to whether they were above or
below median time-to-event endpoints for PFS or TTP
found no significant differences in any of the soluble
proteins studied; there was a modest association between
elevated baseline plasma VEGF-C levels and above-median
OS (P=0.0241).
Safety
All 78 patients received at least one dose of sunitinib and
were included in the safety analyses (Table 2). The most
commonly reported treatment-emergent, all-causality, non-
hematologic adverse events were fatigue, anorexia, nausea,
diarrhea, and stomatitis (Table 2). Most non-hematologic
adverse events were grade 1 or 2. Grade 3 or 4 events
included fatigue (10.3%), anorexia, hand–foot syndrome,
hyperbilirubinemia (6.4% each), and abdominal pain
(5.1%). The most common hematologic toxicities were
thrombocytopenia (61.5% of patients; 34.6% grade 3 or 4,
and one patient with a grade 5 event) and neutropenia
(52.6% of patients, 29.4% grade 3 or 4). Thirteen patients
(16.7%) experienced grade 3 or 4 anemia. There were no
cases of neutropenic fever. Of non-hematologic laboratory
adverse events, blood alkaline phosphatase was increased in
10.3% of the study population and occurred at grade 3, the
maximum grade reported, in only two patients. Increases in
gamma glutamyl transferase were infrequent (2.6%) and of
grade 2 severity.
Twenty-four patients (30.8%) permanently discontinued
study treatment due to an adverse event; in 14 patients, the
adverse events were judged by the investigators to be
treatment related. Non-fatal, treatment-related adverse
events leading to discontinuation were grade 3 fatigue
(n=2) and grades 2 and 4 mucositis, grade 3 nausea, grade
1 ascites, grade 4 thrombocytopenia, grade 3 hand–foot
syndrome, grade 4 abdominal pain plus grade 1 anorexia,
and combined grade 2 thrombocytopenia and grade 1
nausea, stomatitis, fatigue, skin erosion and hand–foot
syndrome (n=1 each). Non-treatment-related discontinua-
tions due to adverse events were attributed by investigators
to the disease under study (n=8) or other illness (n=2;
stomach cancer perforation and infection, respectively).
Table 2 Treatment-emergent, all-causality adverse events (any cycle)
reported in ≥15% of patients
Number of patients (%) (N=78)
All-grade Grades 3/4
Non-hematologic
Fatigue 35 (44.9) 8 (10.3)
Anorexia 35 (44.9) 5 (6.4)
Nausea 32 (41.0) 3 (3.8)
Diarrhea 28 (35.9) 2 (2.6)
Stomatitis 28 (35.9) 1 (1.3)
Vomiting 24 (30.8) 3 (3.8)
Hand–foot syndrome 22 (28.2) 5 (6.4)
Pyrexia 22 (28.2)
Abdominal pain 20 (25.6) 4 (5.1)
Skin discoloration 19 (24.4)
Constipation 17 (21.8) 1 (1.3)
Hypoalbuminemia 15 (19.2)
Rash 14 (17.9)
Mucosal inflammation 13 (16.7) 2 (2.6)
Hyperbilirubinemia 13 (16.7) 5 (6.4)
Hematologic
Thrombocytopenia 48 (61.5)
a 27 (34.6)
Neutropenia 41 (52.6) 23 (29.4)
Leukopenia 30 (38.5) 9 (11.5)
Anemia 29 (37.2) 13 (16.7)
aIncludes one grade 5 event
Fig. 3 Total drug (sunitinib + SU12662) dose-corrected (reference
dose: 50 mg) plasma trough concentration versus cycle/day box plot.
Box boundaries denote 25th and 75th percentiles; lines within the box
show the median value and expected range of the median. Whiskers
indicate the minimum and maximum data values; where outliers are
present (asterisks), whiskers extend to a maximum of 1.5 times the
interquartile range
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treatment-emergent adverse events, all of which were
treatment-related.
Eleven patients (14.1%) died during the reporting period
(during treatment or within 28 days after the last dose of
study drug), with eight of these patients having death as the
reason for discontinuation of the study. Four of the 11
deaths were considered to be treatment-related adverse
events (three during treatment and one within 28 days after
the last dose of sunitinib) and seven due to adverse events
unrelated to treatment (six due to disease progression; one
due to hypotension, depressed level of consciousness and
hypopnea). The deaths considered to be treatment-related
were due to thrombocytopenia and pulmonary embolism;
brain herniation (preceded by upper gastrointestinal bleed-
ing at day 14); cardiac arrest; and brainstem hemorrhage
occurring 21 days after the last dose of study drug,
respectively.
HRQoL
QLQ-C30 questionnaires were completed by 64 patients at
baseline (cycle 1, day 1); completion rates were generally
high during treatment but upon withdrawal from the study
the completion rate fell to 69.2%. From a mean baseline
global health status/HRQoL of 62.3, HRQoL was main-
tained by sunitinib treatment during the first three cycles of
this study, though the domains of diarrhea and reflux
symptoms were noticeably worse compared to baseline.
Beyond cycle 3, HRQoL data were available for <10
patients per cycle due to study discontinuations.
At patients’ last evaluation (end of treatment or
withdrawal from the study), noticeable changes (deteriora-
tion) were observed in most scales and measures of the
EORTC QLQ-C30 and QLQ-STO22 compared to the
baseline. The domains for perceived financial difficulties,
body image, and hair loss did not change noticeably.
Discussion
In this study, sunitinib showed preliminary activity in the
second-line treatment setting in patients with advanced
gastric adenocarcinoma or gastroesophageal junction ade-
nocarcinoma. Following two objective responses in Stage
1, both stages of the study were enrolled, but overall the
study did not meet its primary endpoint, with only two
patients achieving a PR by RECIST for an overall RECIST-
defined ORR of 2.6%. However, the clinical benefit rate
was 7.7% and one-third of patients experienced a best
response of SD. The median OS duration of 6.8 months,
and the median PFS and TTP of 2.3 months with single-
agent sunitinib in this study are comparable with those
reported in the second-line treatment setting in similar
phase II trials of single-agent chemotherapy, such as
docetaxel [31, 32], paclitaxel [33, 34], irinotecan [35], or
mitomycin C [36], as well as various chemotherapy
combinations [4–6]. This level of efficacy is clearly
insufficient to support further study of sunitinib as a
single-agent in this population, although these data support
the proof of concept that sunitinib does affect the late
clinical course of gastric cancer.
Recently, the use of trastuzumab in combination with
chemotherapy was found to significantly prolong survival
when given as first-line treatment for patients with HER2-
positive gastric or gastroesophageal cancer [37]—this is the
first time that a regimen including a targeted agent has been
shown to provide a survival benefit in patients with
advanced gastric cancer. It can be hypothesized that the
progression-delaying effects observed with sunitinib in our
trial might be enhanced if sunitinib is given in combination
with chemotherapy, and this is being investigated in the
first-line treatment setting in phase I trials at present.
In general, the type and frequency of reported adverse
events were consistent with those previously reported with
sunitinib when administered as a single agent [25, 26, 38,
39]. Adverse events were generally manageable, as dose
schedule modifications (mainly dosing delays) were re-
quired in less than half of the patients, though the incidence
of permanent discontinuations due to treatment-related
adverse events was 18%. This included four (5.1%)
treatment-related deaths (thrombocytopenia/pulmonary em-
bolism, brain herniation preceded by upper gastrointestinal
bleeding, cardiac arrest, and one patient who died 21 days
after the last dose of study drug from brainstem hemor-
rhage). The predominant non-fatal, treatment-related ad-
verse events leading to discontinuation were fatigue and
mucositis. Most non-hematologic adverse events were
Grade 1 or 2 in severity. The most common Grade 3 or 4
non-hematologic events included fatigue, anorexia, hand–
foot syndrome, hyperbilirubinemia, and abdominal pain,
each reported in ≤10% of patients. However, the incidence
and severity of hematologic adverse events during sunitinib
treatment was higher in this population than in gastrointes-
tinal stromal tumor (GIST) and metastatic renal cell
carcinoma (mRCC) patients [25, 26]. Grade 3 or 4
neutropenia or thrombocytopenia was reported in approxi-
matelyone-third ofpatients, but onlyone caseofhemorrhagic
thrombocytopenia was reported, and there were no cases of
neutropenic fever. The majority of adverse events were
managed by standard medical intervention and sunitinib
dosing interruption, with or without dose reduction.
Analysis of the HRQoL endpoints measuring gastric
cancer-related symptoms, general cancer-related symptoms,
overall health status and quality of life shows that these
scores were largely maintained during the first three cycles
Invest New Drugs (2011) 29:1449–1458 1455of sunitinib treatment. Given that patients discontinued
sunitinib treatment due to insufficient clinical response, the
subsequent worsening in health status was more likely due
to disease progression than to drug toxicity in this single-
arm study of limited sample size.
Based on the dose-corrected Ctrough data, the pharmacoki-
netics of sunitinib and its metabolite in advanced/metastatic
gastric cancer patients were consistent with previous expe-
rience with sunitinib at 50 mg/day on Schedule 4/2 in
patients with advanced solid tumors [40]. No unexpected
accumulation of sunitinib or its metabolite was observed
throughout the study. Assessment of soluble protein levels
versus measures of clinical outcome only showed associa-
tions between clinical benefit and high sKIT ratio to baseline
at cycle 1 day 28 (P=0.0081), and between clinical benefit
and low VEGF-C ratio at cycle 2 day 1 (P=0.0326).
However, there were a limited number of patients with
clinical benefit to include in these analyses. In general, the
patterns of pharmacodynamic changes in soluble protein
levels observed were similar to those seen in previously
reported sunitinib studies [41].
In exploring the potential of sunitinib in gastric cancer,
several hypotheses can be proposed that may have had an
impact on the limited efficacy observed in this trial. Firstly,
in the absence of known predictive biomarkers, it was not
possible in this trial to select a subset of gastric cancer
patients who might be more likely to respond to sunitinib,
which is in contrast to the ability to preselect HER2-
positive patients likely to be sensitive to trastuzumab in the
ToGA trial [37]. Further understanding of who may benefit
from treatment could help to refine the target population for
future studies. It is also notable that ORR assessed using
RECIST was selected as the primary endpoint of this study.
However, observations with targeted agents in other tumor
types, for example imatinib in GIST [42] and sunitinib in
RCC [43], suggest that one-dimensional RECIST measure-
ments can miss important information about changes in
tumor density and metabolic response. This raises the
question as to whether ORR is the most suitable endpoint
for assessing sunitinib in gastric cancer.
Dose selection and schedule could also be explored
further. On the intermittent schedule used in this and other
studies of sunitinib, pharmacodynamic modulation of
several plasma proteins associated with angiogenesis was
reversible during the off-treatment period [38, 43–45]. This
raises the question of whether continuous administration of
sunitinib might be of benefit, to ensure continuous suppres-
sion of angiogenesis. Ultimately, these hypotheses would all
require testing in a trial setting.
In summary, the preliminary activity and manageable
toxicity observed with sunitinib in this study suggest that
although single-agent sunitinib has insufficient clinical
value as second-line treatment for advanced gastric cancer,
its role in combination with chemotherapy is worthy of
further study. The results of ongoing phase I trials in the
first-linetreatment settingwillprovidemoreinsight intotheuse
of multiple-RTK inhibitors such as sunitinib in the treatment of
advanced gastric cancer.
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